Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation

FEBS Letters
Pavel StrnadM Bishr Omary

Abstract

Mallory bodies (MBs) are characteristic of several liver disorders, and consist primarily of keratins with transglutaminase-generated keratin crosslinks. We tested the effect of the transglutaminase-2 (TG2) inhibitor KCC009 on MB formation in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). KCC009 decreased DDC-induced liver enlargement without affecting MB formation or extent of liver injury. TG2 protein and activity increased after DDC feeding and localized within and outside hepatocytes. KCC009 inhibited DDC-induced hepatomegaly by affecting hepatocyte cell size rather than proliferation. Hence, TG2 is a potential mediator of injury-induced hepatomegaly via modulation of hepatocyte hypertrophy, and KCC009-mediated TG2 inhibition does not affect mouse MB formation.

References

Dec 1, 1972·Analytical Biochemistry·L LorandL Cooperstein
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D J SelkoeY Ihara
Sep 1, 1995·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·M Cadrin, M G Martinoli
Aug 1, 1995·Experimental and Molecular Pathology·Q X YuanS W French
Jun 19, 1998·Neuromuscular Disorders : NMD·H H Goebel
Feb 5, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M Bishr OmaryDiana M Toivola
Oct 9, 2002·Trends in Biochemical Sciences·Laszlo Fesus, Mauro Piacentini
Nov 30, 2002·The Journal of Biological Chemistry·Mathieu LesortGail V W Johnson
Feb 4, 2003·Nature Reviews. Molecular Cell Biology·Laszlo Lorand, Robert M Graham
Feb 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Eunsung JunnM Maral Mouradian
Mar 19, 2003·International Review of Cytology·Harald HerrmannThomas M Magin
Aug 9, 2003·The American Journal of Gastroenterology·Carla EspositoRiccardo Troncone
Oct 21, 2004·The Journal of Pathology·Kurt ZatloukalHelmut Denk
Nov 13, 2004·The New England Journal of Medicine·M Bishr OmaryW H Irwin McLean
Jan 14, 2005·Methods in Cell Biology·Nam-On KuM Bishr Omary
Feb 5, 2005·The Journal of Biological Chemistry·Kristen A Johnson, Robert A Terkeltaub
Feb 16, 2005·Annals of Internal Medicine·Armin Alaedini, Peter H R Green
Sep 9, 2005·Frontiers in Bioscience : a Journal and Virtual Library·Evgeny A ZemskovAlexey M Belkin
Sep 20, 2005·Molecular Cancer Therapeutics·Liya YuanKeith M Rich
Dec 21, 2005·The Journal of Cell Biology·Ikuo NakamichiM Bishr Omary

❮ Previous
Next ❯

Citations

Mar 1, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Raymond KwanM Bishr Omary
Apr 8, 2010·Journal of Leukocyte Biology·Ivana MaticMauro Piacentini
Apr 22, 2008·PLoS Pathogens·Michael T Bethune, Chaitan Khosla
Jan 4, 2012·Pharmacology & Therapeutics·Hilary Grosso, M Maral Mouradian
Sep 14, 2010·Toxicology Letters·Adriana C CochónLeonor C San Martín de Viale
Feb 7, 2009·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·L ElliD Schuppan
Nov 18, 2010·Gene Expression Patterns : GEP·Wataru KimuraKimiko Fukuda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis